{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T20:11:50Z","timestamp":1794514310082,"version":"4.9.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21dm0207070"],"award-info":[{"award-number":["21dm0207070"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21wm0425015"],"award-info":[{"award-number":["21wm0425015"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21wm0425015"],"award-info":[{"award-number":["21wm0425015"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H04820"],"award-info":[{"award-number":["21H04820"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K16928"],"award-info":[{"award-number":["19K16928"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K07424"],"award-info":[{"award-number":["21K07424"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Abnormal \u03b1-synuclein aggregation is a key pathological feature of a group of neurodegenerative diseases known as synucleinopathies, which include Parkinson\u2019s disease (PD), dementia with Lewy bodies and multiple system atrophy (MSA). The pathogenic \u03b2-sheet seed conformation of \u03b1-synuclein is found in various tissues, suggesting potential as a biomarker, but few studies have been able to reliably detect these seeds in serum samples. In this study, we developed a modified assay system, called immunoprecipitation-based real-time quaking-induced conversion (IP\/RT-QuIC), which enables the detection of pathogenic \u03b1-synuclein seeds in the serum of individuals with synucleinopathies. In our internal first and second cohorts, IP\/RT-QuIC showed high diagnostic performance for differentiating PD versus controls (area under the curve (AUC): 0.96 (95% confidence interval (CI) 0.95\u20130.99)\/AUC: 0.93 (95% CI 0.84\u20131.00)) and MSA versus controls (AUC: 0.64 (95% CI 0.49\u20130.79)\/AUC: 0.73 (95% CI 0.49\u20130.98)). IP\/RT-QuIC also showed high diagnostic performance in differentiating individuals with PD (AUC: 0.86 (95% CI 0.74\u20130.99)) and MSA (AUC: 0.80 (95% CI 0.65\u20130.97)) from controls in a blinded external cohort. Notably, amplified seeds maintained disease-specific properties, allowing the differentiation of samples from individuals with PD versus MSA. In summary, here we present a novel platform that may allow the detection of individuals with synucleinopathies using serum samples.<\/jats:p>","DOI":"10.1038\/s41591-023-02358-9","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T12:02:12Z","timestamp":1685361732000},"page":"1448-1455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":323,"title":["Propagative \u03b1-synuclein seeds as serum biomarkers for synucleinopathies"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-5402","authenticated-orcid":false,"given":"Ayami","family":"Okuzumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-0444","authenticated-orcid":false,"given":"Taku","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuko","family":"Nojiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4133-3605","authenticated-orcid":false,"given":"Shin-ichi","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6830-456X","authenticated-orcid":false,"given":"Yoko","family":"Imamichi-Tatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2632-1352","authenticated-orcid":false,"given":"Haruka","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9434-4944","authenticated-orcid":false,"given":"Soichiro","family":"Kakuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-4490","authenticated-orcid":false,"given":"Akihide","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7412-3631","authenticated-orcid":false,"given":"Manabu","family":"Funayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9732-8488","authenticated-orcid":false,"given":"Shinji","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Tsunemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"G\u00e9rardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Mittelbronn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rejko","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Nukina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-2556","authenticated-orcid":false,"given":"Nobutaka","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,29]]},"reference":[{"key":"2358_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi, M. et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 140, 49\u201362 (2020).","journal-title":"Acta Neuropathol."},{"key":"2358_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz, M. et al. Discriminating \u03b1-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature 578, 273\u2013277 (2020).","journal-title":"Nature"},{"key":"2358_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. \u03b1-Synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"2358_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"YC Wong","year":"2017","unstructured":"Wong, Y. C. & Krainc, D. \u03b1-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat. Med. 23, 1\u201313 (2017).","journal-title":"Nat. Med."},{"key":"2358_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","volume":"20","author":"A Iranzo","year":"2021","unstructured":"Iranzo, A. et al. Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 20, 203\u2013212 (2021).","journal-title":"Lancet Neurol."},{"key":"2358_CR6","doi-asserted-by":"publisher","first-page":"7871","DOI":"10.1021\/bi030086j","volume":"42","author":"MJ Volles","year":"2003","unstructured":"Volles, M. J. & Lansbury, P. T. Jr. Zeroing in on the pathogenic form of \u03b1-synuclein and its mechanism of neurotoxicity in Parkinson\u2019s disease. Biochemistry 42, 7871\u20137878 (2003).","journal-title":"Biochemistry"},{"key":"2358_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00401-011-0852-9","volume":"122","author":"GM Halliday","year":"2011","unstructured":"Halliday, G. M., Holton, J. L., Revesz, T. & Dickson, D. W. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 122, 187\u2013204 (2011).","journal-title":"Acta Neuropathol."},{"key":"2358_CR8","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1002\/mds.27894","volume":"34","author":"WG Meissner","year":"2019","unstructured":"Meissner, W. G. et al. Multiple system atrophy: recent developments and future perspectives. Mov. Disord. 34, 1629\u20131642 (2019).","journal-title":"Mov. Disord."},{"key":"2358_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00401-010-0664-3","volume":"119","author":"TG Beach","year":"2010","unstructured":"Beach, T. G. et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 119, 689\u2013702 (2010).","journal-title":"Acta Neuropathol."},{"key":"2358_CR10","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00702-005-0427-9","volume":"113","author":"PH Lee","year":"2006","unstructured":"Lee, P. H. et al. The plasma alpha-synuclein levels in patients with Parkinson\u2019s disease and multiple system atrophy. J. Neural Transm. (Vienna) 113, 1435\u20131439 (2006).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"2358_CR11","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3389\/fneur.2019.01388","volume":"10","author":"CW Chang","year":"2019","unstructured":"Chang, C. W., Yang, S. Y., Yang, C. C., Chang, C. W. & Wu, Y. R. Plasma and serum alpha-synuclein as a biomarker of diagnosis in patients with Parkinson\u2019s disease. Front. Neurol. 10, 1388 (2019).","journal-title":"Front. Neurol."},{"key":"2358_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00702-016-1650-2","volume":"124","author":"J Ding","year":"2017","unstructured":"Ding, J. et al. Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson\u2019s disease. J. Neural Transm. (Vienna) 124, 353\u2013360 (2017).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"2358_CR13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/jnnp-2016-314857","volume":"88","author":"CH Lin","year":"2017","unstructured":"Lin, C. H. et al. Plasma \u03b1-synuclein predicts cognitive decline in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 88, 818\u2013824 (2017).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2358_CR14","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/brain\/awab306","volume":"145","author":"E Lobanova","year":"2021","unstructured":"Lobanova, E. et al. Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinson\u2019s disease. Brain 145, 632\u2013643 (2021).","journal-title":"Brain"},{"key":"2358_CR15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ana.25446","volume":"85","author":"N Candelise","year":"2019","unstructured":"Candelise, N. et al. Seeding variability of different alpha synuclein strains in synucleinopathies. Ann. Neurol. 85, 691\u2013703 (2019).","journal-title":"Ann. Neurol."},{"key":"2358_CR16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul, G. et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann. Clin. Transl. Neurol. 3, 812\u2013818 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"2358_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","volume":"6","author":"BR Groveman","year":"2018","unstructured":"Groveman, B. R. et al. Rapid and ultra-sensitive quantitation of disease-associated \u03b1-synuclein seeds in brain and cerebrospinal fluid by \u03b1Syn RT-QuIC. Acta Neuropathol. Commun. 6, 7 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"2358_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11481-019-09835-4","volume":"14","author":"S Manne","year":"2019","unstructured":"Manne, S. et al. Ultrasensitive detection of aggregated \u03b1-synuclein in glial cells, human cerebrospinal fluid, and brain tissue using the RT-QuIC assay: new high-throughput neuroimmune biomarker assay for parkinsonian disorders. J. Neuroimmune Pharm. 14, 423\u2013435 (2019).","journal-title":"J. Neuroimmune Pharm."},{"key":"2358_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/ana.25447","volume":"85","author":"A van Rumund","year":"2019","unstructured":"van Rumund, A. et al. \u03b1-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism. Ann. Neurol. 85, 777\u2013781 (2019).","journal-title":"Ann. Neurol."},{"key":"2358_CR20","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/mds.27646","volume":"34","author":"UJ Kang","year":"2019","unstructured":"Kang, U. J. et al. Comparative study of cerebrospinal fluid \u03b1-synuclein seeding aggregation assays for diagnosis of Parkinson\u2019s disease. Mov. Disord. 34, 536\u2013544 (2019).","journal-title":"Mov. Disord."},{"key":"2358_CR21","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1093\/brain\/awac115","volume":"145","author":"A Kluge","year":"2022","unstructured":"Kluge, A. et al. Detection of neuron-derived pathological \u03b1-synuclein in blood. Brain 145, 3058\u20133071 (2022).","journal-title":"Brain"},{"key":"2358_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/mds.27907","volume":"35","author":"S Manne","year":"2020","unstructured":"Manne, S. et al. \u03b1-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson\u2019s disease patients. Mov. Disord. 35, 268\u2013278 (2020).","journal-title":"Mov. Disord."},{"key":"2358_CR23","first-page":"1","volume":"78","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. Skin \u03b1-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol. 78, 1\u201311 (2020).","journal-title":"JAMA Neurol."},{"key":"2358_CR24","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/mds.28242","volume":"35","author":"S Manne","year":"2020","unstructured":"Manne, S. et al. Blinded RT-QuIC analysis of \u03b1-synuclein biomarker in skin tissue from Parkinson\u2019s disease patients. Mov. Disord. 35, 2230\u20132239 (2020).","journal-title":"Mov. Disord."},{"key":"2358_CR25","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/brain\/awab005","volume":"144","author":"A Stefani","year":"2021","unstructured":"Stefani, A. et al. Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. Brain 144, 1118\u20131126 (2021).","journal-title":"Brain"},{"key":"2358_CR26","doi-asserted-by":"publisher","first-page":"fcab045","DOI":"10.1093\/braincomms\/fcab045","volume":"3","author":"D Perra","year":"2021","unstructured":"Perra, D. et al. Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies. Brain Commun. 3, fcab045 (2021).","journal-title":"Brain Commun."},{"key":"2358_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13024-021-00491-y","volume":"16","author":"C Bargar","year":"2021","unstructured":"Bargar, C. et al. Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories. Mol. Neurodegener. 16, 82 (2021).","journal-title":"Mol. Neurodegener."},{"key":"2358_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/jnnp-2014-309676","volume":"87","author":"T Hatano","year":"2016","unstructured":"Hatano, T., Saiki, S., Okuzumi, A., Mohney, R. P. & Hattori, N. Identification of novel biomarkers for Parkinson\u2019s disease by metabolomic technologies. J. Neurol. Neurosurg. Psychiatry 87, 295\u2013301 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2358_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40478-018-0587-0","volume":"6","author":"A Okuzumi","year":"2018","unstructured":"Okuzumi, A. et al. Rapid dissemination of alpha-synuclein seeds through neural circuits in an in-vivo prion-like seeding experiment. Acta Neuropathol. Commun. 6, 96 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"2358_CR30","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/s42003-022-03590-8","volume":"5","author":"Y Imamura","year":"2022","unstructured":"Imamura, Y. et al. Quantum-dot-labeled synuclein seed assay identifies drugs modulating the experimental prion-like transmission. Commun. Biol. 5, 636 (2022).","journal-title":"Commun. Biol."},{"key":"2358_CR31","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1212\/01.wnl.0000341769.50075.bb","volume":"72","author":"JA Driver","year":"2009","unstructured":"Driver, J. A., Logroscino, G., Gaziano, J. M. & Kurth, T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432\u2013438 (2009).","journal-title":"Neurology"},{"key":"2358_CR32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3389\/fnagi.2018.00326","volume":"10","author":"G Hipp","year":"2018","unstructured":"Hipp, G. et al. The Luxembourg Parkinsonas Study: a comprehensive approach for stratification and early diagnosis. Front. Aging Neurosci. 10, 326 (2018).","journal-title":"Front. Aging Neurosci."},{"key":"2358_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","volume":"74","author":"M Shahnawaz","year":"2017","unstructured":"Shahnawaz, M. et al. Development of a biochemical diagnosis of Parkinson disease by detection of \u03b1-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol. 74, 163\u2013172 (2017).","journal-title":"JAMA Neurol."},{"key":"2358_CR34","doi-asserted-by":"publisher","first-page":"e930","DOI":"10.1212\/WNL.0000000000012438","volume":"97","author":"M Rossi","year":"2021","unstructured":"Rossi, M. et al. Diagnostic value of the CSF \u03b1-synuclein real-time quaking-induced conversion assay at the prodromal MCI stage of dementia with Lewy bodies. Neurology 97, e930\u2013e940 (2021).","journal-title":"Neurology"},{"key":"2358_CR35","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/brain\/awab431","volume":"145","author":"I Poggiolini","year":"2022","unstructured":"Poggiolini, I. et al. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 145, 584\u2013595 (2022).","journal-title":"Brain"},{"key":"2358_CR36","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/ene.14208","volume":"27","author":"M Niu","year":"2020","unstructured":"Niu, M. et al. A longitudinal study on \u03b1-synuclein in plasma neuronal exosomes as a biomarker for Parkinson\u2019s disease development and progression. Eur. J. Neurol. 27, 967\u2013974 (2020).","journal-title":"Eur. J. Neurol."},{"key":"2358_CR37","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1212\/WNL.0000000000003989","volume":"88","author":"E Antelmi","year":"2017","unstructured":"Antelmi, E., Donadio, V., Incensi, A., Plazzi, G. & Liguori, R. Skin nerve phosphorylated \u03b1-synuclein deposits in idiopathic REM sleep behavior disorder. Neurology 88, 2128\u20132131 (2017).","journal-title":"Neurology"},{"key":"2358_CR38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00401-017-1684-z","volume":"133","author":"K Doppler","year":"2017","unstructured":"Doppler, K. et al. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson\u2019s disease. Acta Neuropathol. 133, 535\u2013545 (2017).","journal-title":"Acta Neuropathol."},{"key":"2358_CR39","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1212\/WNL.0000000000001834","volume":"85","author":"LL Barnes","year":"2015","unstructured":"Barnes, L. L. et al. Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology 85, 528\u2013534 (2015).","journal-title":"Neurology"},{"key":"2358_CR40","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00401-015-1406-3","volume":"129","author":"L Walker","year":"2015","unstructured":"Walker, L. et al. Neuropathologically mixed Alzheimer\u2019s and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol. 129, 729\u2013748 (2015).","journal-title":"Acta Neuropathol."},{"key":"2358_CR41","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00401-017-1717-7","volume":"134","author":"A Kapasi","year":"2017","unstructured":"Kapasi, A., DeCarli, C. & Schneider, J. A. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 134, 171\u2013186 (2017).","journal-title":"Acta Neuropathol."},{"key":"2358_CR42","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/mds.27193","volume":"32","author":"SA Schneider","year":"2017","unstructured":"Schneider, S. A. & Alcalay, R. N. Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature. Mov. Disord. 32, 1504\u20131523 (2017).","journal-title":"Mov. Disord."},{"key":"2358_CR43","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1002\/mds.28667","volume":"36","author":"R Isonaka","year":"2021","unstructured":"Isonaka, R. et al. \u03b1-Synuclein deposition in sympathetic nerve fibers in genetic forms of Parkinson\u2019s disease. Mov. Disord. 36, 2346\u20132357 (2021).","journal-title":"Mov. Disord."},{"key":"2358_CR44","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00401-019-02037-5","volume":"138","author":"S Lohmann","year":"2019","unstructured":"Lohmann, S. et al. Oral and intravenous transmission of \u03b1-synuclein fibrils to mice. Acta Neuropathol. 138, 515\u2013533 (2019).","journal-title":"Acta Neuropathol."},{"key":"2358_CR45","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/2211-5463.13110","volume":"11","author":"S L\u00f6vestam","year":"2021","unstructured":"L\u00f6vestam, S. et al. Seeded assembly in vitro does not replicate the structures of \u03b1-synuclein filaments from multiple system atrophy. FEBS Open Bio 11, 999\u20131013 (2021).","journal-title":"FEBS Open Bio"},{"key":"2358_CR46","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"2358_CR47","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman, S. et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670\u2013676 (2008).","journal-title":"Neurology"},{"key":"2358_CR48","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89, 88\u2013100 (2017).","journal-title":"Neurology"},{"key":"2358_CR49","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov. Disord. 32, 853\u2013864 (2017).","journal-title":"Mov. Disord."},{"key":"2358_CR50","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann, G. et al. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34, 939\u2013944 (1984).","journal-title":"Neurology"},{"key":"2358_CR51","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov. Disord. 25, 2649\u20132653 (2010).","journal-title":"Mov. Disord."},{"key":"2358_CR52","first-page":"473640","volume":"2011","author":"A Yoritaka","year":"2011","unstructured":"Yoritaka, A. et al. Nonmotor symptoms in patients with PARK2 mutations. Parkinsons Dis. 2011, 473640 (2011).","journal-title":"Parkinsons Dis."},{"key":"2358_CR53","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/ene.14009","volume":"26","author":"A Okuzumi","year":"2019","unstructured":"Okuzumi, A. et al. Neuromelanin or DaT-SPECT: which is the better marker for discriminating advanced Parkinson\u2019s disease? Eur. J. Neurol. 26, 1408\u20131416 (2019).","journal-title":"Eur. J. Neurol."},{"key":"2358_CR54","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.febslet.2006.02.032","volume":"580","author":"M Masuda","year":"2006","unstructured":"Masuda, M. et al. Cysteine misincorporation in bacterially expressed human \u03b1-synuclein. FEBS Lett. 580, 1775\u20131779 (2006).","journal-title":"FEBS Lett."},{"key":"2358_CR55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-0716-1495-2_1","volume":"2322","author":"A Okuzumi","year":"2021","unstructured":"Okuzumi, A. et al. \u03b1-Synuclein seeding assay ising RT-QuIC. Methods Mol. Biol. 2322, 3\u201316 (2021).","journal-title":"Methods Mol. Biol."}],"updated-by":[{"DOI":"10.1038\/s41591-025-03521-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02358-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02358-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02358-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T02:15:26Z","timestamp":1737771326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02358-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2358"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02358-9","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,29]]},"assertion":[{"value":"1 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-025-03521-0","URL":"https:\/\/doi.org\/10.1038\/s41591-025-03521-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.H. reports receiving grants and fees unrelated to this research during the conduct of the study; grants from the Japan Society for the Promotion of Science (JSPS), the Japan Agency for Medical Research and Development (AMED), the Japan Science and Technology Agency (JST), the Health and Labour Sciences Research Grant, the International Parkinson and Movement Disorder Society and the Michael J. Fox Foundation for Parkinson\u02bcs Research; personal fees for speakers honoraria from Sumitomo Pharma, Takeda Pharmaceutical, Kyowa Kirin, AbbVie GK, Otsuka Pharmaceutical, Novartis, Ono Pharmaceutical, Eisai, Teijin Pharma and Daiichi Sankyo; and personal fees for consultancies and advisory boards from Sumitomo Pharma, Takeda Pharmaceutical, Kyowa Kirin, Ono Pharmaceutical, Teijin Pharma and PARKINSON Laboratories. N.H. also owns shares in PARKINSON Laboratories (equity stock (8%)). T.H. reports receiving grants from Kyowa Kirin, the Setsuro Fujii Memorial of the Osaka Foundation for Promotion of Fundamental Medical Research, JSPS KAKENHI (under grant no. 21K07424), the Japan Agency for Medical Research and Development (grant nos. 21wm0425015 and 21dk0207055) and Daiichi Sankyo Selects Research Partners for TaNeDS Collaborative Drug Discovery Project and speakers honoraria from Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Kyowa Kirin, Novartis, Sanofi, Eisai and Otsuka Pharmaceutical during the conduct of the study. A.O. reports receiving grants from the research grant for biogenic amines and neurological disorders and JSPS KAKENHI (under grant no. 19K16928) and speakers honoraria from Takeda Pharmaceutical and Kyowa Kirin, during the conduct of the study. R.K. reports receiving grants and fees unrelated to this research during the conduct of the study; grants from the Fonds National de la Recherche (FNR) Luxembourg, the Fondation Veuve-Metz-Tesch Luxembourg, the Leir Foundation, the Michael J. Fox Foundation for Parkinson\u02bcs Research (MJFF), the Parkinson\u02bcs Foundation, the Movement Disorder Society, the European Institute of Innovation and Technology (EIT Health), the Innovative Medicines Initiative (IMI) of the European Union and the European pharmaceutical industry and the European Union\u2019s Horizon 2020 and Horizon Europe research and innovation programs; and personal speaker\u2019s honoraria and\/or travel grants from AbbVie, Zambon and Medtronic. R.K. participated as PI or site-PI for industry-sponsored clinical trials without receiving honoraria. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}